Status:
COMPLETED
Diagnostic Performance of the ID Now™ COVID-19 Screening Test Versus Simplexa™ COVID-19 Direct Assay
Lead Sponsor:
Fondation Hôpital Saint-Joseph
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), first appeared in China, and then spread around the world. In December 2019, a group of pat...
Detailed Description
Early detection with a sensitive technique of COVID-19 is essential to ensure rapid and appropriate patient management, to contain the epidemic and to better understand the global epidemiology of the ...
Eligibility Criteria
Inclusion
- Patient aged ≥ 18 years
- Patient presenting to the emergency room of the GhPSJ and for whom a PCR examination is prescribed by the emergency doctor in charge of the patient
- French-speaking patient
- Patient affiliated with social security or, failing that, with another health insurance system
- Patient capable of giving free, informed and express consent.
Exclusion
- Pregnant or breastfeeding patient.
- Patient under guardianship or curatorship
- Patient deprived of liberty
- Patient under legal protection.
Key Trial Info
Start Date :
November 9 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 9 2022
Estimated Enrollment :
1265 Patients enrolled
Trial Details
Trial ID
NCT04785898
Start Date
November 9 2020
End Date
May 9 2022
Last Update
May 13 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Groupe Hospitalier Paris Saint-Joseph
Paris, Île-de-France Region, France, 75014